Nasdaq Notifies BioCardia of Listing Non-Compliance, Citing Equity Shortfall
BCDA sits 18% above its 52-week low of $1 on light trading volume (0.2× avg).
Summary
BioCardia has received a formal notice from Nasdaq indicating non-compliance with Listing Rule 5550(b)(1) due to its stockholders' equity of $895,000 falling below the required $2.5 million minimum. This notification formalizes a risk previously highlighted in the company's recent 10-K filing (March 24, 2026), which noted a 'Nasdaq delisting risk' and severe liquidity issues with a cash runway only until May 2026. The non-compliance poses a significant threat to BioCardia's public listing, which is crucial for its ability to raise capital and maintain investor confidence, especially for a company of its size. BioCardia has until May 25, 2026, to submit a plan to regain compliance. Investors should monitor the company's proposed compliance plan and any subsequent actions by Nasdaq, as well as potential financing efforts to address the equity and liquidity shortfalls.
At the time of this announcement, BCDA was trading at $1.18 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $13M. The 52-week trading range was $1.00 to $3.20. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Wiseek News.